

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	4D MEDICAL LIMITED
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Livingston
Date of last notice	8 March 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares in which the beneficial interest is held by John Livingston Pty Ltd, an entity controlled by John Livingston (registered holder: Colonial First State Inv Ltd <4916557 JOHN A/C>); and Ordinary shares in which the beneficial interest is held by JKEL Super Pty Ltd, an entity in which John Livingston has a voting power above 20% and thus is deemed by Section 608(3) of the Corporations Act 2001 to have the same relevant interest (registered holder: Colonial First State Inv Ltd <4916510 JKEL A/C>).
Date of change	21 November 2024
No. of securities held prior to change	Direct 636,576 options exercisable at \$0.79 expiring 17 January 2026 Indirect <u>John Livingston Pty Ltd</u> 604,008 fully paid ordinary shares <u>JKEL Super Pty Ltd</u> 1,321,344 fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Options
Number acquired	60,147
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Options issued as a component of director's remuneration (valued at \$36,250 based on the 30-day-VWAP of \$0.6027 as at 1 July 2024).
No. of securities held after change	<p>Direct 636,576 unquoted options exercisable at \$0.79 expiring 17 January 2026</p> <p>60,147 unquoted options with a nil exercise price and expiry date of 30 June 2029.</p> <p>Indirect <u>Colonial First State Inv Ltd <4916557 JOHN A/C> (beneficial holder John Livingston Pty Ltd)</u> 604,008 fully paid ordinary shares</p> <p><u>Colonial First State Inv Ltd <4916510 JKEL A/C (beneficial holder: JKEL Super Pty Ltd</u> 1,321,344 fully paid ordinary shares</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of options as approved at Annual General Meeting on 20 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

+ See chapter 19 for defined terms.

Interest after change	N/A
------------------------------	-----

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.